Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue (2018 - 2021)

Fulcrum Therapeutics (FULC) has reported Non-Current Deffered Revenue for 4 consecutive years, with $1.7 million the latest figure, recorded in Q4 2021.

• In Q4 2021, Non-Current Deffered Revenue fell 43.45% year-over-year to $1.7 million; the TTM figure through Dec 2021 stood at $1.7 million (down 43.45% YoY), while the FY2021 annual figure was $1.7 million, down 43.45% from the prior year.
• Non-Current Deffered Revenue improved to $1.7 million in Q4 2021 per FULC's latest filing, from $1.6 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $6.0 million in Q4 2019 and bottomed at $1.4 million in Q4 2018.
• Historically, Non-Current Deffered Revenue has averaged $2.9 million across 4 years, with a median of $1.7 million in 2021.
• Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue surged 328.74% — and 2021, when it slumped 72.47%.
• Fulcrum Therapeutics' Non-Current Deffered Revenue stood at $1.4 million in 2018, then soared by 328.74% to $6.0 million in 2019, then plunged by 50.57% to $3.0 million in 2020, then sank by 43.45% to $1.7 million in 2021.
• Business Quant data shows FULC's Non-Current Deffered Revenue at $1.7 million in Q4 2021, $1.6 million in Q3 2021, and $1.7 million in Q2 2021.